CTOs on the Move

Nipro Medical

www.nipro.com

 
Nipro provides premium renal medical devices, including dialyzers, bloodlines, AVF needles, as well as high-quality medical surgical products.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.nipro.com
  • 200, Crossing Blvd
    Bridgewater, NJ USA 08807
  • Phone: 908.393.7030

Executives

Name Title Contact Details

Similar Companies

Mitchell and Resnikoff

Mitchell and Resnikoff is a Elkins Park, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Westminster Pharmaceuticals

Westminster Pharmaceuticals is dedicated to improving patient outcomes and reducing the cost of healthcare.

Concordia Pharmaceuticals

Concordia Pharmaceuticals is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

Soliton

Soliton has developed breakthrough science for tattoo removal using Rapid Acoustic Pulse (RAP) technology, which when combined with existing laser technology can rapidly accelerate tattoo removal.